1. Lyscaut: image support from concept to conclusion
Where clinical trials demand the clarity and visual certainty imaging brings, Lyscaut
provides cost-conscious management and unprecedented flexibility in design and
implementation – whether end to end, or at any stage, in any role.
Lyscaut is an entrepreneur, reaching beyond the
normal definition of a medical imaging company to
partner cutting‑ edge expertise around the world in
image transport, visualisation and analysis. By
creating partnerships of specialists with
complementary skills, Lyscaut can provide a uniquely
tailor‑ made, cost‑ effective solution.
Partnerships mean lean management, and lean
management means cost savings. In fact it offers clients
– particularly small and medium‑sized Pharma, Biotech
and CROs ‑ the best of both worlds: partners are chosen
for the quality of their abilities, and those abilities are on
call, not permanently on the payroll.
Lyscaut - IRC partnership
Hybrid molecular
imaging
Oncology
Cachexia
Lyscaut
Imaging
Research Center
Metabolic
imaging
Personalised
medicine
Biomarkers
Obesity
Hybrid Nuc Med
imaging
Inflammation
2. IRC: a special relationship
A case in point is the USA‑ based IRC, an advanced
imaging lab and contract research company with
whom we work on developing the biomarkers pivotal
to measuring progress at every stage of trials.
In parallel, we seek to broaden our expertise through
collaborations at the frontiers of research into
non‑ contrast biomarkers. Fields of study include
companion diagnostics, and personalised medicine
within cardiology, oncology and pathology.
Among those we have worked with, on a regular or
project basis, are Hermes Medical, Heart IT,
DataMagik, Gaea Pharma, Fusion Pharma and
Telemedrev.
We particularly value IRC’s imaging analytics platform
for its ability to tailor solutions to need and achieve
levels of precision and accuracy that reduce the size of
samples needed to reach statistical significance.
With other operational efficiencies, this brings
savings in time, money and resources.
Different partners, same success
Because of partnerships like this combined with
in‑ house expertise, Lyscaut has developed particular
strengths in trialling drugs and devices to mitigate
conditions of inflammation and metabolic syndrome,
selecting the optimal biomarkers and using the most
appropriate modalities to scrutinise data:
Comprehensive, scalable, accountable
With such experience to draw on, we can be relied on
to optimise image workflow from concept to
conclusion. We build in cost‑ effectiveness from the
outset with a design study that includes protocols,
financials and charter development.
We then embark on:
- Multi‑ modality biomarker selection and
development
- Imaging charter development & document
preparation
- Scientific & medical consultancy
- Study protocol design & financials
- Imaging KOL and reader network selection
- Study roll‑ out and management
- Site training and certification
- End‑ to‑ end image logistics, processing and analysis
- Data logging, tracking & reporting and quality
control
- Regulatory and compliance support throughout
- Study close out reporting
- Publication oversight to maximise return on
investment
Conditions Modalities Partners
Body composition:
obesity, cachexia
MRI, MRS, CT, US IRC
Digital
Dermatology
various various
Rheumatology Optical (infrared)
imaging, X‑ Ray,
CT,MRI
modality dependent
MS, Alzheimer’s
Disease
PET, MRI CT Hermes Medical
3. Hospital 1 Hospital 2 Hospital 3
n
i
e
a
l
s
a l
f
l a c
o g f u
c
i
l i
c
Lyscaut:
r
u
c
a m
l f
c
i l
n
a
u
t
s a
l l
r
a
Cost-effective, too
Imaging is growing fast despite its seeming complexity
and supposed cost because of the quality of evidence it
provides. Its ability to highlight differences pre‑ and
post‑ treatment, especially
in tumours, shows it is as much a primary as a
secondary end‑ point. And criticisms of logistical
complexity are behind the curve of the technology we
can bring to bear.
Lyscaut manages an information highway in which
medical images are transported through a process of
anonymised file upload, storage and transfer, remote
access, streaming, or imaging‑ enabled EDC. And
communication is integrated to provide real‑ time
messaging, notification or annotation.
By putting in place such technology, and the expertise
to make best use of it with an international partnership
model, Lyscaut effectively nullifies the perceived cost
premium and opens up the possibility of superior,
image‑ based trials to smaller companies and
organisations who would not previously have
considered them.
Contact EU: Contact USA
EU@lyscaut.com USA@lyscaut.com
Phone: +32-479-838710 Phone: +1-877-472 5227
